New Obicetrapib cholesterol-lowering pill cuts heart attacks, strokes risk
Groundbreaking Study Reveals Obicetrapib’s Dual Benefits A new cholesterol-lowering pill, Obicetrapib, may revolutionize treatment for individuals at high risk of heart attacks and strokes. In a significant international study led by Monash University, researchers discovered that this once-daily oral medication effectively lowers both LDL cholesterol and Pill and lipoprotein (a), two major contributors to cardiovascular disease. The study, named the BROADWAY trial, involved more than 2,500 participants who were either diagnosed with existing heart conditions or had genetically high cholesterol levels. These patients were already receiving the maximum tolerated doses of traditional cholesterol-lowering drugs. Despite this, many continued to struggle